AU2015317466A1 - Abiraterone acetate formulation and methods of use - Google Patents

Abiraterone acetate formulation and methods of use Download PDF

Info

Publication number
AU2015317466A1
AU2015317466A1 AU2015317466A AU2015317466A AU2015317466A1 AU 2015317466 A1 AU2015317466 A1 AU 2015317466A1 AU 2015317466 A AU2015317466 A AU 2015317466A AU 2015317466 A AU2015317466 A AU 2015317466A AU 2015317466 A1 AU2015317466 A1 AU 2015317466A1
Authority
AU
Australia
Prior art keywords
abiraterone acetate
unit dosage
less
sodium
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015317466A
Other languages
English (en)
Inventor
Satya Bhamidipati
H. William Bosch
Matthew CALLAHAN
Jason Coleman
Christopher Hill
Maura Murphy
Paul NEMETH
Marck Norret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Global FZE
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015317466(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of AU2015317466A1 publication Critical patent/AU2015317466A1/en
Assigned to SUN PHARMA GLOBAL FZE reassignment SUN PHARMA GLOBAL FZE Request for Assignment Assignors: ICEUTICA INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
AU2015317466A 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use Abandoned AU2015317466A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
US14/707,922 2015-05-08
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
AU2015317466A1 true AU2015317466A1 (en) 2017-02-23

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015317466A Abandoned AU2015317466A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Country Status (17)

Country Link
EP (1) EP3193857A4 (enrdf_load_stackoverflow)
JP (1) JP2017528457A (enrdf_load_stackoverflow)
KR (2) KR102617537B1 (enrdf_load_stackoverflow)
CN (1) CN106687112A (enrdf_load_stackoverflow)
AP (1) AP2017009804A0 (enrdf_load_stackoverflow)
AU (1) AU2015317466A1 (enrdf_load_stackoverflow)
BR (1) BR112017003219A2 (enrdf_load_stackoverflow)
CA (1) CA2958316A1 (enrdf_load_stackoverflow)
CO (1) CO2017002472A2 (enrdf_load_stackoverflow)
EA (1) EA201790650A1 (enrdf_load_stackoverflow)
IL (1) IL250270B (enrdf_load_stackoverflow)
MD (1) MD20170048A2 (enrdf_load_stackoverflow)
MX (1) MX2017003525A (enrdf_load_stackoverflow)
PH (1) PH12017500239A1 (enrdf_load_stackoverflow)
SG (1) SG11201701139YA (enrdf_load_stackoverflow)
TN (2) TN2017000098A1 (enrdf_load_stackoverflow)
WO (1) WO2016044701A1 (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN110891549A (zh) 2017-04-07 2020-03-17 玛亚实验室公司 改善治疗剂的溶解度和生物利用度的方法
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物
CA3131034A1 (en) 2019-03-06 2020-09-10 Matthew J. Sharp Abiraterone prodrugs
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
KR20220166856A (ko) * 2020-04-16 2022-12-19 타반타 테라퓨틱스 헝가리 인코포레이티드 전립선암을 치료하기 위한 방법 및 조성물
CA3177094A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CA3207282A1 (en) 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141013B2 (ja) * 2009-04-24 2017-06-07 イシューティカ ピーティーワイ リミテッド 商業的規模での封入ナノ粒子の製造
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方

Also Published As

Publication number Publication date
KR20230014878A (ko) 2023-01-30
TN2017000098A1 (en) 2018-10-19
KR20170070025A (ko) 2017-06-21
KR102617537B1 (ko) 2023-12-22
IL250270A0 (en) 2017-03-30
JP2017528457A (ja) 2017-09-28
IL250270B (en) 2021-02-28
CO2017002472A2 (es) 2017-07-11
EP3193857A4 (en) 2018-04-11
MX2017003525A (es) 2017-06-21
BR112017003219A2 (pt) 2017-11-28
CA2958316A1 (en) 2016-03-24
WO2016044701A1 (en) 2016-03-24
AP2017009804A0 (en) 2017-03-31
PH12017500239A1 (en) 2017-07-03
SG11201701139YA (en) 2017-03-30
MD20170048A2 (ro) 2017-08-31
EA201790650A1 (ru) 2017-07-31
CN106687112A (zh) 2017-05-17
KR102491439B1 (ko) 2023-01-25
EP3193857A1 (en) 2017-07-26
TN2018000318A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2018241103B2 (en) Abiraterone Acetate Formulation
US9889144B2 (en) Abiraterone acetate formulation and methods of use
KR102491439B1 (ko) 아비라테론 아세테이트 제제 및 사용 방법
US10292990B2 (en) Abiraterone steroid formulation
HK40018807A (en) Abiraterone acetate formulation
HK40018807B (en) Abiraterone acetate formulation
OA18485A (en) Abiraterone acetate formulation and methods of use.
OA18169A (en) Abiraterone acetate formulation
HK1220162B (en) Abiraterone acetate formulation
HK40020084A (zh) 乙酸阿比特龙酯制剂
HK40020084B (zh) 乙酸阿比特龙酯制剂
HK1234990A1 (en) Abiraterone acetate formulation and methods of use

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUN PHARMA GLOBAL FZE

Free format text: FORMER APPLICANT(S): ICEUTICA INC.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period